Antioxidants and cardiovascular disease: Still a topic of interest

Environmental Health and Preventive Medicine

Volumn 9, Issue 5, 2004, Pages 200-213

  Nojiri, Shuko ^a   Daida, Hiroyuki ^a   Inaba, Yutaka ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

antioxidants; atherosclerosis; cardiovascular disease; oxidative stress; vitamins

Indexed keywords

EID: 85163615032     PISSN: 1342078X     EISSN: 13474715     Source Type: Journal    
DOI: 10.1007/BF02898101     Document Type: Review

References (139)

1. Wagakunino Hoken Tokei (H13). Tokyo: Health and Welfare Statistics Association, 2001 (Magazine in Japanese).
2. Weisburger JH. Lifestyle, health and disease prevention: the underlying mechanisms. Eur J Cancer Prev. 2002; 11: S1–7. DOI: 10.1097/00008469-200202000-00001
3. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA. 2002; 288: 2569–2578. DOI: 10.1001/jama.288.20.2569
4. National Research Council, USA. Committee on Diet and Health, Implication for reducing Chronic Disease risk. Washington, DC: National Academy of Sciences, 1989.
5. nd end, 1989.
6. Hirvonen T, Pietinen P, Virtanen M, et al. Intake of flavonols and flavones and risk of coronary heart disease in male smokers. Epidemiology, 2001; 12: 62–67. DOI: 10.1097/00001648-200101000-00011
7. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev. 2002; 54: 599–618. DOI: 10.1124/pr.54.4.599
8. Hinderliter AL, Caughey M. Assessing endothelial function as a risk factor for cardiovascular disease. Curr Atheroscler Rep. 2003; 5: 506–513. DOI: 10.1007/s11883-003-0042-x
9. Samman S, Sivarajah G, Man JC, Ahmad ZI, Petocz P, Caterson ID. A mixed fruit and vegetable concentrate increases plasma antioxidant vitamins and folate and lowers plasma homocysteine in men. J Nutr. 2003; 133: 2188–2193.
10. Gey KF. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Acta Cardiol. 1989; 44: 493–494.
11. Gey KF. The antioxidant hypothesis of cardiovascular disease: epidemiology and mechanisms. Biochem Soc Trans. 1990; 18: 1041–1045.
12. Gaziano JM, Manson JE, Ridker PM, Buring JE, Hennekens CH. beta carotene therapy for chronic stable angina. Circulation. 1990; 82: Abstract 0796.
13. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology. 1992; 3: 194–202. DOI: 10.1097/00001648-199205000-00003
14. Gey KF, Stahelin HB, Eichholzer M. Poor plasma status of carotene and vitamin C is associated with higher mortality from ischemic heart disease and stroke: Basel Prospective study. Clin Investig. 1993; 71: 3–6. DOI: 10.1007/BF00210955
15. Hennekens CH, Gaziano JM, Manson JE, Buring JE. Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Am J Clin Nutr. 1995; 62: 1377S-1380S.
16. Gaziano JM. Antioxidants in cardiovascular disease: randomized trials. Nutrition. 1996; 12: 583–588. DOI: 10.1016/S0899-9007(96)00184-0
17. Rimm EB, Stampfer MJ. The role of antioxidants in preventive cardiology. Curr Opin Cardiol. 1997; 12: 188–194. DOI: 10.1097/00001573-199703000-00016
18. Steinbrecher UP. Dietary antioxidants and cardioprotection—fact or fallacy? Can J Physiol Pharmacol. 1997; 75: 228–233. DOI: 10.1139/cjpp-75-3-228
19. Manson JE, Bassuk SS, Stampfer MJ. Does vitamin E supplementation prevent cardiovascular events? J Womens Health (Larchmt). 2003; 12: 123–136.
20. Davies KJ. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp. 1995; 61: 1–31.
21. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003; 108: 1912–1916. DOI: 10.1161/01.CIR.0000093660.86242.BB
22. Loscalzo J. Oxidant stress: a key determinant of atherothrombosis. Biochem Soc Trans. 2003; 31: 1059–1061.
23. Maxwell SR, Lip GY. Free radicals and antioxidants in cardiovascular disease. Br J Clin Pharmacol. 1997; 44: 307–317. DOI: 10.1046/j.1365-2125.1997.t01-1-00594.x
24. Chen K, Thomas SR, Keaney JF Jr. Beyond LDL oxidation: ROS in vascular signal transduction. Free Radic Biol Med. 2003; 35: 117–132. DOI: 10.1016/S0891-5849(03)00239-9
25. Fri B. Cardiovascular disease and nutrient antioxidants: role of low-density lipoprotein oxidation. Crit Rev Food Sci Nutr. 1995; 35: 83–98.
26. Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem. 2001; 82: 674–682. DOI: 10.1002/jcb.1198
27. Ruef J, Peter K, Nordt TK, Runge MS, Kubler W, Bode C. Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb Haemost 1999; 82: 32–37.
28. Keaney JF Jr, Vita JA. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovasc Dis. 1995; 38: 129–154. DOI: 10.1016/S0033-0620(05)80003-9
29. Halliwell B. Albumin—an important extracellular antioxidant? Biochem Pharmacol. 1988; 15: 569–571. DOI: 10.1016/0006-2952(88)90126-8
30. Rush JW, Sandiford SD. Plasma glutathione peroxidase in healthy young adults: influence of gender and physical activity. Clin Biochem. 2003; 36: 345–351. DOI: 10.1016/S0009-9120(03)00039-0
31. Martin A, Frei B. Both intracellular and extra cellular vitamin C inhibits atherogenic modification of LDL by human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1997; 17: 1583–1590.
32. May JM, Cobb CE, Mendiratta S, Hill KE, Burk RF. Reduction of the ascorbyl free radical to ascorbate by thioredoxin reductase. J Biol Chem. 1998; 273: 23039–23045. DOI: 10.1074/jbc.273.36.23039
33. Giugliano D. Dietary antioxidants for cardiovascular prevention. Nutr Metab Cardiovasc Dis. 2000; 10: 38–44.
34. Rice-Evans CA, Miller NJ, Bolwell PG, et al. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic Res. 1995; 22: 375–383. DOI: 10.3109/10715769509145649
35. Sanz MJ, Ferrandiz ML, Cejudo M, et al. Influence of a series of natural flavonoids on free radical generating systems and oxidative stress. Xenobiotica. 1994; 24: 689–699.
36. Kessler M, Ubeaud G, Jung L. Anti- and pro-oxidant activity of rutin and quercetin derivatives. J Pharm Pharmacol. 2003; 55: 131–142. DOI: 10.1211/002235702559
37. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992; 339: 1523–1526. DOI: 10.1016/0140-6736(92)91277-F
38. Cooke JP. Nutriceuticals for cardiovascular health. Am J Cardiol. 1998; 82: 43S-46S.
39. Basu TK, Dickerson JWT. In: Vitamins ad Human Health and Disease. Oxford: Cab International, 1996.
40. Daily Reference Intakes for vitamin C, vitamin E, Selenium, and Carotenoids. Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of DRIs, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. Washington DC: National Academy of Sciences, 2000.
41. Dietary Reference Values for food energy and nutrients for the United Kingdom, 41. London: HMSO, 1991.
42. COMA, Department of Health Report on Health and Social Subjects no 41. Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. Report of the Panel on Dietary Reference Values of the Committee on the Medical Aspects of Food Policy (COMA). Department of Health RHSS 41. London: HMSO, 1991.
43. Human vitamin and mineral requirements. Report of a joint FAO/WHO expert consultation, Bankok, Thailand, Genova: World Health Organization Food and Agriculture Organization of the United Nations, 2002.
44. Recommended Daily Allowances for Japan. Tokyo: Ministry of Health and Welfare, 2000.
45. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr. 1991; 53: 326S-334S.
46. Hertog MG, Kromhout D, Aravanis C, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med. 1995; 155: 381–386. DOI: 10.1001/archinte.155.4.381
47. Matilainen T, Vartiainen E, Puska P, et al. Plasma ascorbic acid concentrations in the Republic of Karelia, Russia and in North Karelia, Finland. Eur J Clin Nutr. 1996; 50: 115–120.
48. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993; 328: 1450–1456. DOI: 10.1056/NEJM199305203282004
49. Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol. 1994; 139: 1180–1189.
50. Morris DL, Kritchevsky SB, Davis CE. Serum carotenoids and coronary heart disease. The Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study. JAMA. 1994; 272: 1439–1441. DOI: 10.1001/jama.272.18.1439
51. Gaziano JM, Manson JE, Branch LG, Colditz GA, Willett WC, Buring JE. A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann Epidemiol. 1995; 5: 255–260. DOI: 10.1016/1047-2797(94)00090-G
52. Pandey DK, Shekelle R, Selwyn BJ, et al. Dietary vitamin C and beta-carotene and risk of death in middle-aged men. The Western Electric Study. Am J Epidemiol. 1995; 142: 1269–1278.
53. Klipstein-Grobusch K, Geleijnse JM, den Breeijen JH, et al. Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999; 69: 261–266.
54. Ford ES, Giles WH. Serum vitamins, carotenoids, and angina pectoris: findings from the National Health and Nutrition Examination Survey III. Ann Epidemiol. 2000; 10: 106–116. DOI: 10.1016/S1047-2797(99)00038-1
55. Osganian SK, Stampfer MJ, Rimm E, et al. Dietary carotenoids and risk of coronary artery disease in women. Am J Clin Nutr. 2003; 77: 1390–1399.
56. Kritchevsky SB, Shimakawa T, Tell GS, et al. Dietary antioxidants and carotid artery wall thickness. Atherosclerosis Risk in Communities Study. The ARIC Study. Circulation. 1995; 92: 2142–2150.
57. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996; 334: 1156–1162. DOI: 10.1056/NEJM199605023341803
58. Nyyssonen K, Parviainen MT, Salonen R, et al. Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ. 1997; 314: 634–638.
59. Simon JA, Hudes ES. Serum ascorbic acid and cardiovascular disease prevalence in U.S. adults: the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 1999; 9: 358–365. DOI: 10.1016/S1047-2797(99)00008-3
60. Simon JA, Hudes ES, Tice JA. Relation of serum ascorbic acid to mortality among US adults. J Am Coll Nutr. 2001; 20: 255–263.
61. Muntwyler J, Hennekens CH, Manson JE, Buring JE, Gaziano JM. Vitamin supplement use in a low-risk pepulation of US male physicians and subsequent cardiovascular mortality. Arch Intern Med. 2002; 162: 1472–1476. DOI: 10.1001/archinte.162.13.1472
62. Osganian SK, Stampfer MJ, Rimm E, et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol. 2003; 42: 246–252. DOI: 10.1016/S0735-1097(03)00575-8
63. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Eng J Med. 1993; 328: 1444–1449. DOI: 10.1056/NEJM199305203282003
64. Losonczy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr. 1996; 64: 190–196.
65. Evans RW, Shaten BJ, Day BW, Kuller LH. Prospective association between lipid soluble antioxidants and coronary heart disease in men. The Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1998; 147: 180–186.
66. Brubacher D, Moser U, Jordan P. Vitamin C concentrations in plasma as a function of intake: a meta-analysis. Int J Vitam Nutr Res. 2000; 70: 226–237. DOI: 10.1024/0300-9831.70.5.226
67. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003; 361: 2017–2023. DOI: 10.1016/S0140-6736(03)13637-9
68. van’t Veer P, Jansen MC, Klerk M, Kok FJ. Fruits and vegetables in the prevention of cancer and cardiovascular disease. Public Health Nutr. 2000; 3: 103–107.
69. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993; 342: 1007–1011. DOI: 10.1016/0140-6736(93)92876-U
70. Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ. 1996; 312: 478–481.
71. Jarvinen R, Seppanen R, Knekt P. Short-term and long-term reproducibility of dietary history interview data. Int J Epidemiol. 1993; 22: 520–517. DOI: 10.1093/ije/22.3.520
72. Joshipura KJ, Hu FB, Manson JE, et al. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med. 2001; 134: 1106–1114.
73. Hertog MG, Sweetnam PM, Fehily AM, Elwood PC, Kromhout D. Antioxidant flavonols and ischemic heart disease in a Welsh population of men: the Caerphilly Study. Am J Clin Nutr. 1997; 65: 1489–1494.
74. Fraser GE, Shavlik DJ. Risk factors for all-cause and coronary heart disease mortality in the oldest-old. The Adventist Health Study. Arch Intern Med. 1997; 157: 2249–2258. DOI: 10.1001/archinte.157.19.2249
75. Sesso HD, Gaziano JM, Liu S, et al. Flavonoid intake and the risk of cardiovascular disease in women. Am J Clin Nutr. 2003; 77: 1400–1408.
76. Kritchevsky SB. beta-Carotene, carotenoids and the prevention of coronary heart disease. J Nutr. 1999; 129: 5–8.
77. Rissanen TH, Voutilainen S, Nyyssonen K, Salonen R, Kaplan GA, Salonen JT. Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr. 2003; 77: 133–138.
78. Rissanen T, Voutilainen S, Nyyssonen K, Salonen JT. Lycopene, atherosclerosis, and coronary heart disease. Exp Biol Med (Maywood). 2002; 227: 900–907.
79. Meydani M. Nutrition interventions in aging and age-associated disease. Ann NY Acad Sci. 2001; 928: 226–235. DOI: 10.1111/j.1749-6632.2001.tb05652.x
80. McKay DL, Blumberg JB. The role of tea in human health: an update. J Am Coll Nutr. 2002; 21: 1–13.
81. Rietveld A, Wiseman S. Antioxidant effects of tea: evidence from human clinical trials. J Nutr. 2003; 133: 3285S-3292S.
82. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and validity of an expanded self-administered semi-quantitive food frequency questionnaire among male health professionals. Am J Epidemiol. 1992; 135: 1114–1126.
83. Heitmann BL, Lissner L, Osler M. Do we eat less fat, or just report so? Int J Obes Relat Metab Disord. 2000; 24: 435–442. DOI: 10.1038/sj.ijo.0801176
84. Yokoi H, Daida H, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol. 1997; 30: 855–862. DOI: 10.1016/S0735-1097(97)00270-2
85. Daida H, Kuwabara Y, Yokoi H, et al. Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]). Am J Cardiol. 2000; 86: 550–552. DOI: 10.1016/S0002-9149(00)01013-4
86. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med. 1997; 337: 365–372. DOI: 10.1056/NEJM199708073370601
87. Tardif JC, Cote G, Lesperance J, Gosselin G, et al. Impact of residual plaque burden after balloon angioplasty in the Multi-Vitamins and Probucol (MVP) trial. Can J Cardiol. 2001; 17: 49–55.
88. Wayner DD, Burton GW, Ingold KU, Locke S. Quantitative measurement of the total, peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. The important contribution made by plasma proteins. FEBS Lett. 1985; 187: 33–37. DOI: 10.1016/0014-5793(85)81208-4
89. Cao G, Alessio HM, Cutler RG. Oxygen-radical absorbance capacity assay for antioxidants. Free Radic Biol Med. 1993; 14: 303–311. DOI: 10.1016/0891-5849(93)90027-R
90. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol. 1994; 234: 279–293. DOI: 10.1016/0076-6879(94)34095-1
91. Ghiselli A, Serafini M, Ferro-Luzzi A. New approaches for measuring plasma or serum antioxidant capacity: a methodological note. Free Radic Biol Med. 1994; 16: 135–137. DOI: 10.1016/0891-5849(94)90251-8
92. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem. 1996; 239: 70–76. DOI: 10.1006/abio.1996.0292
93. Rigatteri S, Bufon A, Ramazotti V, et al. Oxidative stress inschemia-reperfusion injury: assessment by three independent biochemical markers. Ital Heart J. 2000; 1: 68–72.
94. Tomasetti M, Alleva R, Piva R, et al. Evaluation of ischemia-reperfusion damage during coronary angioplasty. Electrocardiographic assessment and biochemical modifications in blood from the coronary sinus. Ital Heart J. 2000; 1: 216–220.
95. Kummerow FA, Olinescu RM, Fleischer L, Handler B, Shinkareva SV. The relationship of oxidazed lipids to coronary artery stenosis. Atherosclerosis. 2000; 149: 181–190. DOI: 10.1016/S0021-9150(99)00378-0
96. Nojiri S, Daida H, Mokuno H, et al. Association of serum antioxidant capacity with coronary artery disease in middle-aged men. Jap Heart J. 2001; 42: 677–690. DOI: 10.1536/jhj.42.677
97. Blot WJ, Li JY, Taylor PR, Guo W, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993; 85: 1483–1492. DOI: 10.1093/jnci/85.18.1483
98. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994; 330: 1029–1035. DOI: 10.1056/NEJM199404143301501
99. Rapola JM, Virtamo J, Haukka JK, et al. Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. JAMA. 1996; 275: 693–698. DOI: 10.1001/jama.275.9.693
100. Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998; 158: 668–675. DOI: 10.1001/archinte.158.6.668
101. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996 2; 334: 1150–1155. DOI: 10.1056/NEJM199605023341802
102. Redlich CA, Chung JS, Cullen MR, Blaner WS, Van Bennekum AM, Berglund L. Effect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET). Atherosclerosis. 1999; 145: 425–432. DOI: 10.1016/S0021-9150(99)00266-X
103. Manson JE, Buring JE, Satterfield S, Hennekens CH. Base-line characteristics of participants in the Physicians’ Health Study: a randomized trial of aspirin and beta-carotene in U.S. physicians. Am J Prev Med. 1991; 7: 150–154.
104. No author, Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med. 1999; 321: 129–135.
105. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians’ Health Study II—a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol. 2000; 10: 125–134. DOI: 10.1016/S1047-2797(99)00042-3
106. Hereberg S, Preziosi P, Briancon S, et al. A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study—design, methods, and participant characteristies. SUpplementation en VItamines et Mineraux AntioXydants. Control Clin Trials. 1998; 19: 336–351. DOI: 10.1016/S0197-2456(98)00015-4
107. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women’s Health Study. J Natl Cancer Inst. 1999; 91: 2102–2106. DOI: 10.1093/jnci/91.24.2102
108. Arad Y, Newstein D, Roth M, Guerci AD. Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification. Control Clin Trials. 2001; 22: 553–572. DOI: 10.1016/S0197-2456(01)00146-5
109. Salonen RM, Nyyssonen K, Kaikkonen J, et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation. 2003; 107: 947–953. DOI: 10.1161/01.CIR.0000050626.25057.51
110. The WACS Research Group. A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. Ann Epidemiol. 1995; 5: 261–269. DOI: 10.1016/1047-2797(94)00091-7
111. Mason PJ, Manson JE, Sesso HD, et al. Blood pressure and risk of secondary cardiovascular events in women: the Women’s Antioxidant Cardiovascular Study (WACS). Circulation. 2004; 109: 1623–1629. DOI: 10.1161/01.CIR.0000124488.06377.77
112. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996; 347: 781–786. DOI: 10.1016/S0140-6736(96)90866-1
113. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997; 349: 1715–1720. DOI: 10.1016/S0140-6736(97)01234-8
114. Angiotensin-converting enzyme (ACE) inhibition in the secondary prevention of vascular disease: the Heart Outcomes Prevention Evaluation (HOPE) Trial and its substudies. Curr Atheroscler Rep. 2000; 2: 361–362
115. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001; 103: 919–925.
116. Marchioli R, Schweiger C, Tavazzi L, Valagussa F. Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Lipids. 2001; 36: S119-S116. DOI: 10.1007/s11745-001-0694-8
117. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002 23; 105: 1897–1903. DOI: 10.1161/01.CIR.0000014682.14181.F2
118. Hsia J, Alderman EL, Verter JI, et al. Women’s angiographic vitamin and estrogen trial: design and methods. Control Clin Trials. 2002; 23: 708–727. DOI: 10.1016/S0197-2456(02)00237-4
119. Heart Protection Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 23–33. DOI: 10.1016/S0140-6736(02)09328-5
120. Hennekens CH, Buring JE. Epdemiology in medicine. Philadelphia: Lippincott Williams & Wilkins, 1987.
121. Hodis HN, Mack WJ, LaBree L, et al. VEAPS Research Group, Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation. 2002; 106: 1453–1459. DOI: 10.1161/01.CIR.0000029092.99946.08
122. Leeson CP, Mann A, Kattenhorn M, Deanfield JE, Lucas A, Muller DP. Plasma vitamin E, total antioxidant status and vascular function in young adults. Eur J Clin Invest. 2002; 32: 889–894. DOI: 10.1046/j.1365-2362.2002.01085.x
123. Halliwell B. Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? Cardiovasc Res. 2000; 47: 410–418. DOI: 10.1016/S0008-6363(00)00097-3
124. Eastwood MA. Interaction of dietary antioxidants in vivo: how fruit and vegetables prevent disease? QJM. 1999; 92: 527–530. DOI: 10.1093/qjmed/92.9.527
125. Patrick L. Beta-carotene: the controversy continues. Altern Med Rev. 2000; 5: 530–545.
126. Jialal I, Fuller CJ, Huet BA. The effect of α-tocopherol supplementation on LDL oxidation: a dose-response study. Arteriscler Thromb Vasc Biol. 1995; 15: 190–198.
127. Gey KF. Vitamins E plus C and interacting conutrients required for optimal health. A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. Biofactors. 1998; 7: 113–174.
128. Parthasarathy S, Khan-Merchant N, Penumetcha M, Khan BV, Santanam N. Did the antioxidant trials fail to validate the oxidation hypothesis? Curr Atheroscler Rep. 2001; 3: 392–398. DOI: 10.1007/s11883-001-0077-9
129. Heinecke JW. Clinical trials of vitamin E in coronary artery disease: is it time to reconsider the low-density lipoprotein oxidation hypothesis? Curr Atheroscler Rep. 2003; 5: 83–87. DOI: 10.1007/s11883-003-0075-1
130. Lampe JW. Health effects of vegetables and fruit: assessing mechanisms of action in human experimental studies. Am J Clin Nutr. 1999; 70: 475S-490S.
131. Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr. 1999; 69: 1086–1107.
132. Bakalova RA, Hadzhimitova V, Ribarov S. Relationships between serum levels of autoantibodies against oxidized low density lipoproteins, lipid-soluble antioxidants and apolipo-protein B in patients with coronary heart disease. Gen Physiol Biophys. 2000; 19: 103–113.
133. Ottonello L, Frumento G, Arduino N, Dapino P, Tortolina G, Dallegri F. Immune complex stimulation of neutrophil apoptosis: investigating the involvement of oxidative and nonoxidative pathways. Free Radic Biol Med. 2001; 30: 161–169. DOI: 10.1016/S0891-5849(00)00453-6
134. Meydani M. Soluble adhesion molecules: surrogate markers of cardiovascular disease? Nutr Rev. 2003; 61: 63–68. DOI: 10.1301/nr.2003.febr.63-68
135. Calder PC, Kew S. The immune system: a target for functional foods? Br J Nutr. 2002; 88: S165-S177. DOI: 10.1079/BJN2002682
136. Hasler CM, Kundrat S, Wool D. Functional foods and cardiovascular disease. Curr Atheroscler Rep. 2000; 2: 467–475. DOI: 10.1007/s11883-000-0045-9
137. Meraji S, Abuja PM, Hayn M, et al. Relationship between classic risk factors, plasma antioxidants and indicators of oxidant stress in angina pectoris (AP) in Tehran. Atherosclerosis. 2000; 150: 403–412. DOI: 10.1016/S0021-9150(99)00394-9
138. Kristenson M, Kucinskiene Z, Schafer-Elinder L, Leanderson P, Tagesson C. Lower serum levels of beta-carotene in Lithuanian men are accompanied by higher urinary excretion of the oxidative DNA adduct, 8-hydroxydeoxyguanosine. The LiVicordia study. Nutrition. 2003; 19: 11–15. DOI: 10.1016/S0899-9007(02)00837-7
139. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003; 425: 191–196. DOI: 10.1038/nature01960